Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Welcome and Introduction to Vi3C

Varsha Gandhi, PhD, on Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Aug

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Welcome and Introduction to Vi3C

Varsha Gandhi, PhD, on Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

What Is the Optimal PSA to Determine Prostate Cancer Treatment Efficacy

Can Newborn Genetic Testing Identify Cancer Predisposition Genes

FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma

Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

QOL Impact of Postmastectomy Chest Wall Radiotherapy 5-Year Follow-up